FastWave Medical announced that the United States Patent and Trademark Office (USPTO) issued it another intravascular lithotripsy (IVL) utility patent.
This marks the fifth IVL utility patent in the past three years for the company, which earned one last month for its novel next-generation laser-IVL technology.
Minneapolis-based FastWave develops laser-based IVL technology for treating calcific artery disease. Its platform offers durable and fast energy delivery with enhanced sonic output. The system helps to navigate complex arterial anatomy through a high-performing catheter.
FastWave currently has its IVL technology under evaluation in a first-in-human study that kicked off earlier this year.
The latest patent bolster’s the company’s next-generation design for treating calcified arteries in those with occlusive vascular disease. The company says it aims to address gaps in existing IVL options while enhancing ease of use and patient safety. According to the company, calcific disease is one of the most difficult challenges faced in treating blood flow-limiting vascular blockages.
“This issuance of FastWave’s fifth patent from the USPTO marks another milestone for our company and demonstrates clear progress with our unique IVL portfolio,” commented Scott Nelson, co-founder and CEO. “The FastWave team highly values the collaboration with our medical advisors, translating real-world insights into compelling clinical solutions for the benefit of physicians and their patients.”
